血液培養検査市場規模、シェア、動向、2031年までの世界予測

世界の血液培養検査市場は、2026年の66億6,000万米ドルから2031年には89億4,000万米ドルへと、年平均成長率（CAGR）6.1%に達するとMarketsandMarketsでは予測しています。市場の成長は、血流感染症（BSI）、敗血症、および医療関連感染症（HAI）の発生率の上昇や、薬剤耐性（AMR）への懸念の高まりによって後押しされています。血液培養は、血流中の生存微生物を検出し、適切な抗菌薬治療の判断を支援するための重要な診断手法であり続けています。入院患者数、外科手術件数、ならびに重症患者や免疫不全患者の増加も、血液培養検査の実施件数増加に寄与しています。さらに、自動血液培養システム、迅速微生物同定技術、統合型微生物検査ワークフローの導入拡大に加え、検査室のインフラ整備が進んでいることも、市場の成長を加速させています。

調査範囲：

本調査レポートでは、血液培養検査市場を以下の区分で分析しています：製品（消耗品、機器、ソフトウェア・サービス）、手法（従来型／手動式血液培養、自動血液培養）、技術（培養法、分子生物学的検査、プロテオミクス）、用途（菌血症、真菌血症、抗酸菌検出）、エンドユーザー（病院検査室、リファレンスラボ、学術研究機関、その他）、および地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）。

本レポートは、血液培養検査市場の成長に影響を与える主要因（促進要因、阻害要因、機会、課題）に関する詳細情報を提供します。また、主要な業界プレーヤーについて詳細な分析を行い、事業概要、ソリューション、および主要戦略（提携、共同開発、事業拡大、契約締結、新製品投入、市場における最近の動向など）に関する知見を提供します。さらに、血液培養検査のエコシステムにおける新興企業（スタートアップ）の競合分析も含まれています。

本レポートを購入すべき理由：

本レポートは、血液培養検査市場全体およびそのサブセグメントにおける推定収益情報を提供することで、市場のリーダー企業や新規参入企業を支援します。ステークホルダーは、本レポートを通じて競争環境を把握し、より深い洞察を得ることで、自社の事業の立ち位置を明確にし、適切な市場参入戦略を策定することが可能になります。また、市場の動向を理解し、主要な促進要因、阻害要因、機会、課題に関する情報を得る上でも役立ちます。

本レポートでは、以下の点に関する知見を提供します。

血液培養検査市場の成長に影響を与える要因の分析：主要な促進要因（敗血症患者数および治療費の増加、慢性疾患を抱える高齢者人口の急増、院内血流感染症の高い発生率、迅速な検査結果が得られる診断技術への需要拡大、世界的な感染症の高い有病率）、阻害要因（自動血液培養装置の高価格、熟練した検査技師の不足）、機会（新興国における成長機会、薬剤耐性微生物の特定ニーズの増大）、および課題（従来の血液培養ワークフローに伴う長い検査所要時間、血液培養のコンタミネーションや分析前段階でのエラー）

• 製品開発・イノベーション：血液培養検査市場における次世代技術、研究開発活動、および新製品投入に関する詳細な情報
• 市場開拓：有望な市場に関する包括的な情報（地域別の市場分析を含む）
• 市場の多角化：新製品、未開拓地域、最近の動向、および投資活動に関する網羅的な情報
• 競合分析：Waters Corporation（米国）、bioMérieux（フランス）、Thermo Fisher Scientific, Inc.（米国）、DiaSorin S.p.A.（イタリア）といった主要企業の市場シェア、成長戦略、製品ポートフォリオに関する詳細な評価

Report Description

The global blood culture tests market is anticipated to grow from USD 6.66 billion in 2026 to USD 8.94 billion by 2031, reflecting a CAGR of 6.1%. Market growth is supported by the rising incidence of bloodstream infections (BSIs), sepsis, and healthcare-associated infections (HAIs), along with increasing concerns regarding antimicrobial resistance (AMR). Blood culture remains an important diagnostic approach for detecting viable microorganisms in the bloodstream and supporting appropriate antimicrobial treatment decisions. The increasing number of hospital admissions, surgical procedures, and critically ill and immunocompromised patients is further contributing to blood culture testing volumes. Additionally, the growing adoption of automated blood culture systems, rapid microbial identification technologies, and integrated microbiology workflows, coupled with expanding diagnostic laboratory infrastructure, is accelerating market growth.

“Consumables to register the highest CAGR in the blood culture tests market from 2026 to 2031”

Based on product, the consumables segment is likely to record the highest CAGR during the forecast period. This segment is primarily driven by the recurring utilization of blood culture bottles, culture media, reagents, and other associated consumables required for routine blood culture testing. Unlike instruments, which are generally capital purchases with relatively long replacement cycles, blood culture bottles and related consumables are required for each test, creating sustained demand in proportion to testing volumes. Increasing diagnosis of sepsis and bloodstream infections, rising hospital and critical care admissions, and greater emphasis on early identification of causative pathogens are contributing to higher consumption across hospital microbiology and diagnostic laboratories. Furthermore, the expanding installed base of automated blood culture platforms is generating recurring demand for compatible aerobic, anaerobic, and pediatric blood culture bottles and media, further strengthening the segment’s position in the global market.

“Bacteremia segment captured the largest share of the blood culture tests market in 2025”

Based on application, the bacteremia segment accounted for the largest market share in 2025, owing to the widespread use of blood cultures for the detection of bacterial bloodstream infections and identification of causative pathogens. Bacteremia can occur secondary to infections originating from the respiratory tract, urinary tract, gastrointestinal tract, skin and soft tissues, as well as from intravascular catheters and other invasive procedures, resulting in substantial testing demand across hospital settings. Blood culture remains a key diagnostic method for confirming viable bacteria in the bloodstream and obtaining isolates for subsequent pathogen identification and antimicrobial susceptibility testing (AST).

“Asia Pacific to register fastest growth rate in blood culture tests market between 2026 and 2031”

Based on region, Asia Pacific is expected to witness the fastest growth rate during the forecast period. The regional market growth is supported by expanding healthcare infrastructure, increasing healthcare expenditure, and continued development of hospital and clinical laboratory capabilities across emerging economies. The substantial burden of infectious diseases, bloodstream infections, sepsis, and healthcare-associated infections, coupled with large patient populations and increasing hospital admissions, is driving demand for blood culture testing across the region. Governments and private healthcare providers are investing in diagnostic laboratory infrastructure, microbiology capabilities, hospital capacity, and healthcare accessibility, supporting a gradual transition from conventional workflows toward automated blood culture systems in several markets. Furthermore, growing awareness of antimicrobial resistance, antimicrobial stewardship, and the importance of early pathogen identification, along with increasing adoption of automated microbiology platforms and rapid diagnostic technologies, is contributing to market expansion. Major countries supporting regional growth include China, India, Japan, South Korea, and other rapidly developing Asia Pacific healthcare markets.

Breakdown of primary participants in the blood culture tests market is as follows:

• By Company Type: Tier 1 (31%), Tier 2 (40%), and Tier 3 (29%)
• By Designation: C-level Executives (30%), Directors (24%), and Others (46%)
• By Region: North America (52%), Europe (20%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

Key players in the blood culture tests market are Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), DiaSorin S.p.A. (Italy), Danaher Corporation (US), Bruker Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Accelerate Diagnostics, Inc (US), and Autobio Diagnostics Co., Ltd (China).

Research Coverage:

This research report categorizes the blood culture tests market by product (consumables, instruments, and software & services), method (conventional/manual blood culture and automated blood culture), technology (culture-based, molecular, and proteomics), application (bacteremia, fungemia, and mycobacterial detection), end user (hospital laboratories, reference laboratories, academic research laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the blood culture tests market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the market. This report covers the competitive analysis of upcoming startups in the blood culture tests ecosystem.

Reasons to Buy This Report:

The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall blood culture tests market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Increasing number of sepsis patients and cost of treatment, Rapid growth in geriatric population with chronic diseases, High incidence of nosocomial bloodstream infections, Growing demand for rapid diagnostic techniques with faster turnaround times, High prevalence of infectious diseases globally), restraints (High cost of automated blood culture instruments, Lack of trained laboratory technicians) opportunities (Growth opportunities in emerging economies, Increased need to identify antibiotic-resistant microorganisms) and Challenges (Long turnaround time associated with conventional blood culture workflows, Blood culture contamination and pre-analytical errors) influencing the blood culture tests market growth

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the blood culture tests market
• Market Development: Comprehensive information about lucrative markets; the report analyzes the blood culture tests market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood culture tests market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), and DiaSorin S.p.A. (Italy)

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED & REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
2 EXECUTIVE SUMMARY 43
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 43
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 45
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 46
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 48
3.1 BLOOD CULTURE TESTS MARKET OVERVIEW 48
3.2 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2026 VS. 2031 49
3.3 BLOOD CULTURE TESTS MARKET, BY METHOD, 2026 VS. 2031 49
3.4 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2026 VS. 2031 50
3.5 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2026 VS. 2031 50
3.6 BLOOD CULTURE TESTS MARKET, BY END USER, 2026 VS. 2031 51
3.7 BLOOD CULTURE TESTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
4 MARKET OVERVIEW 52
4.1 INTRODUCTION 52
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Increasing number of sepsis patients and rising cost of treatment 53
4.2.1.2 Rapid growth in geriatric population with chronic diseases 53
4.2.1.3 High incidence of bloodstream infections 53
4.2.1.4 Growing demand for rapid diagnostic techniques 54
4.2.1.5 High prevalence of infectious diseases 54
4.2.2 RESTRAINTS 55
4.2.2.1 High cost of automated blood culture instruments 55
4.2.2.2 Lack of trained laboratory technicians 56
4.2.3 OPPORTUNITIES 56
4.2.3.1 Growth opportunities in emerging economies 56
4.2.3.2 Increased need to identify antibiotic-resistant microorganisms 57
4.2.4 CHALLENGES 57
4.2.4.1 Long turnaround time associated with conventional blood culture workflows 57
4.2.4.2 Blood culture contamination and pre-analytical errors 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.3.1 UNMET NEEDS IN BLOOD CULTURE TESTS MARKET 58
4.3.2 WHITE SPACE OPPORTUNITIES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.4.1 INTERCONNECTED MARKETS 60
4.4.2 CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 62
4.5.1 KEY MOVES & STRATEGIC FOCUS 62
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 BARGAINING POWER OF SUPPLIERS 64
5.1.2 BARGAINING POWER OF BUYERS 64
5.1.3 THREAT OF NEW ENTRANTS 64
5.1.4 THREAT OF SUBSTITUTES 64
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.2 MACROECONOMIC INDICATORS 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS & FORECAST 65
5.3 SUPPLY CHAIN ANALYSIS 66
5.4 VALUE CHAIN ANALYSIS 68
5.5 ECOSYSTEM ANALYSIS 69
5.5.1 BLOOD CULTURE TESTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70
5.6 PRICING ANALYSIS 70
5.6.1 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS,
BY KEY PLAYER, 2024–2026 71
5.6.2 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS,
BY REGION, 2024–2026 72
5.7 TRADE ANALYSIS 73
5.7.1 IMPORT SCENARIO (HS CODE 382100) 73
5.7.2 EXPORT SCENARIO (HS CODE 382100) 74
5.8 KEY CONFERENCES & EVENTS, 2026–2027 74
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.10 INVESTMENT & FUNDING SCENARIO 76

5.11 CASE STUDY ANALYSIS 76
5.11.1 ENHANCED STAINING AND WORKFLOW PROTOCOLS IMPROVE DETECTION OF FASTIDIOUS ORGANISMS IN POSITIVE BLOOD CULTURES 76
5.11.2 RAPID BLOOD CULTURE IDENTIFICATION AND ANTIMICROBIAL STEWARDSHIP REDUCE TIME TO OPTIMAL THERAPY 77
5.12 IMPACT OF 2025 US TARIFFS ON BLOOD CULTURE TESTS MARKET 78
5.12.1 INTRODUCTION 78
5.12.2 KEY TARIFF RATES 78
5.12.3 PRICE IMPACT ANALYSIS 79
5.12.4 IMPACT ON REGION 79
5.12.4.1 North America 79
5.12.4.2 Europe 79
5.12.4.3 Asia Pacific 79
5.12.5 IMPACT ON END-USE INDUSTRIES 80
5.12.5.1 Hospital laboratories 80
5.12.5.2 Reference laboratories 80
5.12.5.3 Academic research laboratories 80
5.12.5.4 Other end users 80
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81
6.1 KEY TECHNOLOGIES 81
6.1.1 CULTURE-BASED TECHNOLOGIES 81
6.1.2 MOLECULAR TECHNOLOGIES 81
6.2 COMPLEMENTARY TECHNOLOGIES 81
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING 81
6.3 TECHNOLOGY/PRODUCT ROADMAP 82
6.4 PATENT ANALYSIS 83
6.4.1 LIST OF MAJOR PATENTS 84
6.5 FUTURE APPLICATIONS 84
6.6 IMPACT OF AI/GENERATIVE AI ON BLOOD CULTURE TESTS MARKET 85
6.6.1 INTRODUCTION 85
6.6.2 TOP USE CASES & MARKET POTENTIAL 86
6.6.3 KEY COMPANIES IMPLEMENTING AI 87
6.6.4 FUTURE OF AI 87
7 SUSTAINABILITY & REGULATORY LANDSCAPE 88
7.1 REGIONAL REGULATIONS & COMPLIANCE 88
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
7.1.2 INDUSTRY STANDARDS 90

7.2 SUSTAINABILITY INITIATIVES 91
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN BLOOD CULTURE TESTS 91
7.2.1.1 Eco-friendly initiatives 91
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 92
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 93
8.1 DECISION-MAKING PROCESS 93
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 93
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 93
8.2.2 BUYING CRITERIA 94
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94
8.4 UNMET NEEDS ACROSS VARIOUS END USERS 96
8.5 MARKET PROFITABILITY 97
8.5.1 REVENUE POTENTIAL 97
8.5.2 COST DYNAMICS 97
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 97
9 BLOOD CULTURE TESTS MARKET, BY OFFERING 99
9.1 INTRODUCTION 100
9.2 CONSUMABLES 100
9.2.1 BLOOD CULTURE MEDIA 102
9.2.1.1 Aerobic blood culture media 105
9.2.1.1.1 Growing blood culture volumes to support aerobic media market growth 105
9.2.1.2 Pediatric aerobic blood culture media 108
9.2.1.2.1 Rising pediatric sepsis burden to drive demand for specialized low-volume blood culture bottles 108
9.2.1.3 Anaerobic blood culture media 110
9.2.1.3.1 Increased need for routine diagnosis of bacteria in blood culture to drive segment 110
9.2.1.4 Mycobacterial blood culture media 113
9.2.1.4.1 Persistent global TB burden to drive demand for mycobacterial blood culture media 113
9.2.1.5 Fungi/yeast blood culture media 115
9.2.1.5.1 Easy identification and characterization of special fungal species to drive segment 115
9.2.2 ASSAY KITS & REAGENTS 117
9.2.2.1 Increased need for rapid identification of bacteria and yeast from positive blood cultures to drive market 117
9.2.3 BLOOD CULTURE ACCESSORIES 119
9.2.3.1 Growing number of blood culture tests to drive market 119

9.3 INSTRUMENTS 122
9.3.1 AUTOMATED BLOOD CULTURE SYSTEMS 125
9.3.1.1 Need for automated imaging systems and advanced algorithms to drive market 125
9.3.2 SUPPORTING LABORATORY EQUIPMENT 128
9.3.2.1 Incubators 130
9.3.2.1.1 Incubators to provide optimal environment with adequate temperature and oxygen levels for microbial growth 130
9.3.2.2 Colony counters 132
9.3.2.2.1 Colony counters to increase direct image scanning and analysis capability 132
9.3.2.3 Microscopes 134
9.3.2.3.1 Growing emphasis on rapid preliminary identification to fuel demand for microscopes 134
9.3.2.4 Gram stainers 136
9.3.2.4.1 Gram strainers to guide initial antibiotic section and appropriate empirical therapy 136
9.3.2.5 Other supporting equipment 139
9.4 SOFTWARE & SERVICES 141
9.4.1 INCREASED NEED FOR AUTOMATED SYSTEMS IN HOSPITAL-BASED LABORATORIES TO DRIVE MARKET 141
10 BLOOD CULTURE TESTS MARKET, BY METHOD 144
10.1 INTRODUCTION 145
10.2 CONVENTIONAL/MANUAL BLOOD CULTURES 145
10.2.1 LOWER CAPITAL REQUIREMENTS TO DRIVE ADOPTION OF CONVENTIONAL BLOOD CULTURE METHODS IN RESOURCE-CONSTRAINED SETTINGS 145
10.3 AUTOMATED BLOOD CULTURES 148
10.3.1 NEED FOR FASTER TURNAROUND TIMES TO FUEL TRANSITION TOWARD AUTOMATED BLOOD CULTURE METHODS 148
11 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY 152
11.1 INTRODUCTION 153
11.2 CULTURE-BASED TECHNOLOGIES 153
11.2.1 ADVANCEMENTS IN AUTOMATED DETECTION TO STRENGTHEN CULTURE-BASED TECHNOLOGIES SEGMENT 153
11.3 MOLECULAR TECHNOLOGIES 156
11.3.1 PCR 158
11.3.1.1 Reduced risk of contamination and easy detection of bloodstream infections to drive segment 158
11.3.2 MICROARRAYS 161
11.3.2.1 Determination of better genotyping characterization and identification of bacterial infections to drive segment 161
11.3.3 PNA-FISH 163
11.3.3.1 Rapid species-level identification to strengthen role of PNA-FISH in bloodstream infection diagnosis 163
11.4 OTHER TECHNOLOGIES 165
12 BLOOD CULTURE TESTS MARKET, BY APPLICATION 168
12.1 INTRODUCTION 169
12.2 BACTEREMIA 169
12.2.1 GROWING INCIDENCE OF SEPSIS CASES GLOBALLY TO DRIVE MARKET 169
12.3 FUNGEMIA 171
12.3.1 INCREASING INCIDENCE OF BLOODSTREAM INFECTIONS TO DRIVE MARKET 171
12.4 MYCOBACTERIAL DETECTION 174
12.4.1 HIGH GLOBAL TB BURDEN AND CONCENTRATION OF CASES IN HIGH-RISK POPULATIONS TO DRIVE DEMAND 174
13 BLOOD CULTURE TESTS MARKET, BY END USER 177
13.1 INTRODUCTION 178
13.2 HOSPITAL LABORATORIES 178
13.2.1 INCREASED ABILITY TO CONDUCT LARGE VOLUME OF BLOOD CULTURE TESTS TO DRIVE MARKET 178
13.3 REFERENCE LABORATORIES 181
13.3.1 GROWING REFERRAL AND SPECIALIZED TESTING NEEDS TO FUEL REFERENCE LABORATORY DEMAND 181
13.4 ACADEMIC RESEARCH LABORATORIES 183
13.4.1 GROWING FOCUS ON NOVEL DIAGNOSTIC DEVELOPMENT TO FUEL BLOOD CULTURE TESTING IN RESEARCH LABORATORIES 183
13.5 OTHER END USERS 185
14 BLOOD CULTURE TESTS MARKET, BY REGION 188
14.1 INTRODUCTION 189
14.2 NORTH AMERICA 190
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 195
14.2.2 US 196
14.2.2.1 Rising sepsis burden and antimicrobial resistance to drive demand for blood culture testing in US 196
14.2.3 CANADA 200
14.2.3.1 Increasing MRSA bloodstream infection burden to strengthen demand 200
14.3 BLOOD CULTURE TESTS MARKET: VOLUME ANALYSIS 205
14.3.1 INTRODUCTION 205
14.3.2 NORTH AMERICA: BLOOD CULTURE SETS VOLUME 205
14.4 EUROPE 206
14.4.1 EUROPE: MACROECONOMIC OUTLOOK 210
14.4.2 GERMANY 211
14.4.2.1 Expanding healthcare investment and inpatient care spending to drive adoption 211

14.4.3 UK 215
14.4.3.1 Rising AMR-related bacteremia and E. coli prevalence to expand blood culture testing 215
14.4.4 FRANCE 219
14.4.4.1 Rising healthcare expenditure and high physician density to strengthen adoption 219
14.4.5 ITALY 223
14.4.5.1 Expanding microbiology surveillance and continued healthcare investment to support Italy’s market 223
14.4.6 SPAIN 228
14.4.6.1 Growing elderly population and healthcare utilization to sustain demand 228
14.4.7 REST OF EUROPE 232
14.5 ASIA PACIFIC 237
14.5.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 242
14.5.2 CHINA 242
14.5.2.1 Expanding healthcare investment and hospital capacity to drive blood culture testing demand in China 242
14.5.3 JAPAN 247
14.5.3.1 Extensive hospital infrastructure to sustain demand 247
14.5.4 INDIA 251
14.5.4.1 Rising government healthcare expenditure to support expansion of diagnostic and laboratory infrastructure 251
14.5.5 REST OF ASIA PACIFIC 255
14.6 LATIN AMERICA 260
14.6.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 264
14.6.2 BRAZIL 265
14.6.2.1 Growth in hospital-service expenditure to support modernization of Brazil’s clinical diagnostic infrastructure 265
14.6.3 MEXICO 269
14.6.3.1 Strengthening AMR laboratory requirements to support adoption 269
14.6.4 REST OF LATIN AMERICA 273
14.7 MIDDLE EAST & AFRICA 278
14.7.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 278
15 COMPETITIVE LANDSCAPE 283
15.1 INTRODUCTION 283
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 283
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BLOOD CULTURE TESTS MARKET 283
15.3 REVENUE ANALYSIS, 2023–2025 285
15.4 MARKET SHARE ANALYSIS, 2025 285

15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 288
15.5.1 STARS 288
15.5.2 EMERGING LEADERS 288
15.5.3 PERVASIVE PLAYERS 288
15.5.4 PARTICIPANTS 288
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 290
15.5.5.1 Company footprint 290
15.5.5.2 Region footprint 290
15.5.5.3 Offering footprint 291
15.5.5.4 Method footprint 291
15.5.5.5 Technology footprint 292
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 292
15.6.1 PROGRESSIVE COMPANIES 292
15.6.2 RESPONSIVE COMPANIES 292
15.6.3 DYNAMIC COMPANIES 293
15.6.4 STARTING BLOCKS 293
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 294
15.6.5.1 Detailed list of key startups/SMEs 294
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 294
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 295
15.7 COMPANY VALUATION & FINANCIAL METRICS 295
15.7.1 FINANCIAL METRICS 295
15.7.2 COMPANY VALUATION 296
15.8 BRAND/PRODUCT COMPARISON 296
15.9 COMPETITIVE SCENARIO 297
15.9.1 PRODUCT LAUNCHES & APPROVALS 297
15.9.2 DEALS 298
16 COMPANY PROFILES 299
16.1 KEY PLAYERS 299
16.1.1 WATERS CORPORATION 299
16.1.1.1 Business overview 299
16.1.1.2 Products offered 300
16.1.1.3 Recent developments 302
16.1.1.3.1 Product approvals 302
16.1.1.3.2 Deals 302
16.1.1.4 MnM view 303
16.1.1.4.1 Right to win 303
16.1.1.4.2 Strategic choices 303
16.1.1.4.3 Weaknesses & competitive threats 303

16.1.2 BIOMÉRIEUX 304
16.1.2.1 Business overview 304
16.1.2.2 Products offered 305
16.1.2.3 Recent developments 307
16.1.2.3.1 Product launches 307
16.1.2.4 MnM view 307
16.1.2.4.1 Right to win 307
16.1.2.4.2 Strategic choices 307
16.1.2.4.3 Weaknesses & competitive threats 307
16.1.3 THERMO FISHER SCIENTIFIC, INC. 308
16.1.3.1 Business overview 308
16.1.3.2 Products offered 309
16.1.3.3 Recent developments 310
16.1.3.3.1 Deals 310
16.1.3.4 MnM view 311
16.1.3.4.1 Right to win 311
16.1.3.4.2 Strategic choices 311
16.1.3.4.3 Weaknesses & competitive threats 311
16.1.4 DANAHER CORPORATION 312
16.1.4.1 Business overview 312
16.1.4.2 Products offered 313
16.1.4.3 MnM view 314
16.1.4.3.1 Right to win 314
16.1.4.3.2 Strategic choices 314
16.1.4.3.3 Weaknesses & competitive threats 314
16.1.5 F. HOFFMANN-LA ROCHE LTD. 315
16.1.5.1 Business overview 315
16.1.5.2 Products offered 316
16.1.5.3 Recent developments 317
16.1.5.3.1 Product launches 317
16.1.5.4 MnM view 318
16.1.5.4.1 Right to win 318
16.1.5.4.2 Strategic choices 318
16.1.5.4.3 Weaknesses & competitive threats 318
16.1.6 DIASORIN S.P.A. 319
16.1.6.1 Business overview 319
16.1.6.2 Products offered 320
16.1.6.3 Recent developments 322
16.1.6.3.1 Product approvals 322

16.1.7 BRUKER CORPORATION 323
16.1.7.1 Business overview 323
16.1.7.2 Products offered 324
16.1.7.3 Recent developments 325
16.1.7.3.1 Product launches & approvals 325
16.1.7.3.2 Deals 326
16.1.8 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 327
16.1.8.1 Business overview 327
16.1.8.2 Products offered 328
16.1.8.3 Recent developments 329
16.1.8.3.1 Product launches 329
16.1.9 AUTOBIO DIAGNOSTICS CO., LTD. 330
16.1.9.1 Business overview 330
16.1.9.2 Products offered 331
16.1.9.3 Recent developments 332
16.1.9.3.1 Deals 332
16.1.10 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD. 333
16.1.10.1 Business overview 333
16.1.10.2 Products offered 334
16.2 OTHER PLAYERS 335
16.2.1 HIMEDIA LABORATORIES PVT. LTD. 335
16.2.2 BIOBASE GROUP 336
16.2.3 LABOTRONICS SCIENTIFIC 337
16.2.4 HARDY DIAGNOSTICS 338
16.2.5 BIOLOG, INC. 339
16.2.6 ZHUHAI DEER BIOENGINEERING CO., LTD. 340
16.2.7 ZHUHAI MEIHUA MEDICAL TECHNOLOGY CO. LTD. 341
16.2.8 FISON INSTRUMENTS LTD. 342
16.2.9 BINDER GMBH 343
16.2.10 LABTRON EQUIPMENT LTD. 344
16.2.11 LABNICS LTD. 345
16.2.12 COPAN ITALIA S.P.A. 346
16.2.13 GREINER BIO-ONE INTERNATIONAL GMBH 347
16.2.14 LIOFILCHEM S.R.L. 348
16.2.15 TITAN BIOTECH LTD. 349

17 RESEARCH METHODOLOGY 350
17.1 RESEARCH DATA 350
17.2 RESEARCH APPROACH 350
17.2.1 SECONDARY RESEARCH 350
17.2.1.1 Key data from secondary sources 351
17.2.2 PRIMARY DATA 352
17.2.2.1 Key data from primary sources 354
17.2.2.2 Key industry insights 355
17.3 MARKET SIZE ESTIMATION 356
17.3.1 BOTTOM-UP APPROACH 357
17.3.1.1 Approach 1: Company revenue estimation approach 357
17.3.1.2 Approach 2: Presentations of companies and primary interviews 357
17.3.1.3 Growth forecast 358
17.3.2 TOP-DOWN APPROACH 358
17.4 MARKET BREAKDOWN & DATA TRIANGULATION 360
17.5 MARKET SHARE ANALYSIS 361
17.6 RESEARCH ASSUMPTIONS 361
17.6.1 GROWTH RATE ASSUMPTIONS 361
17.7 RESEARCH LIMITATIONS 362
17.8 RISK ASSESSMENT 362
18 APPENDIX 363
18.1 DISCUSSION GUIDE 363
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 368
18.3 CUSTOMIZATION OPTIONS 370
18.4 RELATED REPORTS 370
18.5 AUTHOR DETAILS 371

LIST OF TABLES

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010, 2023,
AND 2024 (MILLION PEOPLE) 55
TABLE 2 TOTAL TUBERCULOSIS INCIDENCE, BY REGION, 2024 55
TABLE 3 BLOOD CULTURE TESTS MARKET: PORTER’S FIVE FORCES ANALYSIS 64
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 65
TABLE 5 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 71
TABLE 6 AVERAGE SELLING PRICE OF BLOOD CULTURE TEST PRODUCTS, BY REGION, 2024–2026 (USD) 72
TABLE 7 IMPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 73
TABLE 8 EXPORT DATA FOR HS CODE 382100-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 74
TABLE 9 BLOOD CULTURE TESTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 74
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 78
TABLE 11 LIST OF MAJOR PATENTS PERTAINING TO BLOOD CULTURE TESTS MARKET,
2023–2025 84
TABLE 12 KEY COMPANIES IMPLEMENTING AI IN BLOOD CULTURE TESTS MARKET 87
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 18 GLOBAL STANDARDS IN BLOOD CULTURE TESTS MARKET 90
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 93
TABLE 20 KEY BUYING CRITERIA, BY OFFERING 94
TABLE 21 ADOPTION BARRIERS & INTERNAL CHALLENGES 95
TABLE 22 BLOOD CULTURE TESTS MARKET: UNMET NEEDS ACROSS VARIOUS END USERS 96
TABLE 23 BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 100
TABLE 24 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 100
TABLE 25 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY REGION,
2024–2031 (USD MILLION) 101
TABLE 26 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES,
BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 27 EUROPE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 28 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 102
TABLE 29 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES,
BY COUNTRY, 2024–2031 (USD MILLION) 102
TABLE 30 EXAMPLES OF BLOOD CULTURE MEDIA 103
TABLE 31 BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 103
TABLE 32 BLOOD CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 104
TABLE 33 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 104
TABLE 34 EUROPE: BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 104
TABLE 35 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 105
TABLE 36 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 105
TABLE 37 AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 106
TABLE 38 NORTH AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 39 EUROPE: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 107
TABLE 40 ASIA PACIFIC: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 107
TABLE 41 LATIN AMERICA: AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 107
TABLE 42 PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 109
TABLE 43 NORTH AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 44 EUROPE: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 45 ASIA PACIFIC: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 46 LATIN AMERICA: PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 47 ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 111
TABLE 48 NORTH AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 49 EUROPE: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 112
TABLE 50 ASIA PACIFIC: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 112
TABLE 51 LATIN AMERICA: ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112
TABLE 52 MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 113
TABLE 53 NORTH AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 54 EUROPE: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 114
TABLE 55 ASIA PACIFIC: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 56 LATIN AMERICA: MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 57 FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 115
TABLE 58 NORTH AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 59 EUROPE: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 116
TABLE 60 ASIA PACIFIC: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 61 LATIN AMERICA: FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 62 EXAMPLES OF BLOOD CULTURE ASSAY KITS & REAGENTS 117
TABLE 63 BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 64 NORTH AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 65 EUROPE: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 66 ASIA PACIFIC: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 67 LATIN AMERICA: BLOOD CULTURE ASSAY KITS & REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 68 EXAMPLES OF BLOOD CULTURE ACCESSORIES 120
TABLE 69 BLOOD CULTURE ACCESSORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 70 NORTH AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 71 EUROPE: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 72 ASIA PACIFIC: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 73 LATIN AMERICA: BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 74 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 123
TABLE 75 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 76 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 77 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 78 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 79 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 80 EXAMPLES OF AUTOMATED BLOOD CULTURE SYSTEMS 125
TABLE 81 AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 82 NORTH AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 83 EUROPE: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 84 ASIA PACIFIC: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 85 LATIN AMERICA: AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 86 SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 128
TABLE 87 SUPPORTING LABORATORY EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 88 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 89 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 90 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 91 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 92 INCUBATORS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 93 NORTH AMERICA: INCUBATORS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 131
TABLE 94 EUROPE: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 95 ASIA PACIFIC: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 96 LATIN AMERICA: INCUBATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 97 COLONY COUNTERS MARKET, BY REGION, 2024–2031 (USD MILLION) 133
TABLE 98 NORTH AMERICA: COLONY COUNTERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 99 EUROPE: COLONY COUNTERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 100 ASIA PACIFIC: COLONY COUNTERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 101 LATIN AMERICA: COLONY COUNTERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 102 MICROSCOPES MARKET, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 103 NORTH AMERICA: MICROSCOPES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 104 EUROPE: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 105 ASIA PACIFIC: MICROSCOPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 106 LATIN AMERICA: MICROSCOPES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 107 GRAM STAINERS MARKET, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 108 NORTH AMERICA: GRAM STAINERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 109 EUROPE: GRAM STAINERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 110 ASIA PACIFIC: GRAM STAINERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 111 LATIN AMERICA: GRAM STAINERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 112 OTHER SUPPORTING EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 113 NORTH AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 114 EUROPE: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 115 ASIA PACIFIC: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 116 LATIN AMERICA: OTHER SUPPORTING EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 117 BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY REGION,
2024–2031 (USD MILLION) 141
TABLE 118 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 119 EUROPE: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 120 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 121 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 122 BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 145
TABLE 123 EXAMPLES OF CONVENTIONAL/MANUAL BLOOD CULTURE PRODUCTS 146
TABLE 124 CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY REGION,
2024–2031 (USD MILLION) 147
TABLE 125 NORTH AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 126 EUROPE: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 127 ASIA PACIFIC: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 128 LATIN AMERICA: CONVENTIONAL/MANUAL BLOOD CULTURES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 129 EXAMPLES OF AUTOMATED BLOOD CULTURE PRODUCTS 149
TABLE 130 AUTOMATED BLOOD CULTURES MARKET, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 131 NORTH AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 132 EUROPE: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 133 ASIA PACIFIC: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 134 LATIN AMERICA: AUTOMATED BLOOD CULTURES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 135 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 153
TABLE 136 BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES,
BY REGION, 2024–2031 (USD MILLION) 154
TABLE 137 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 138 EUROPE: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 139 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 140 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 141 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 142 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 143 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 144 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 145 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 146 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 147 BLOOD CULTURE TESTS MARKET FOR PCR, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 148 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 149 EUROPE: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 150 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 151 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 152 BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 153 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 154 EUROPE: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 155 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 156 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MICROARRAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 157 BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 158 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 159 EUROPE: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 160 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 161 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 162 EXAMPLES OF MALDI-TOF MS SYSTEMS 166
TABLE 163 BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2024–2031 (USD MILLION) 166
TABLE 164 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 165 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 166 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 167 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 168 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169
TABLE 169 BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 170 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 171 EUROPE: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 172 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 173 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 174 BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 175 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 176 EUROPE: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 177 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 178 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 179 BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY REGION, 2024–2031 (USD MILLION) 175
TABLE 180 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 181 EUROPE: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 182 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 183 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 184 BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 178
TABLE 185 BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 186 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 187 EUROPE: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 188 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 189 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 190 BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 181
TABLE 191 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 192 EUROPE: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 193 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 194 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 195 BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 184
TABLE 196 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 197 EUROPE: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 198 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 199 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR ACADEMIC & RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 200 BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 186
TABLE 201 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 202 EUROPE: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 203 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 204 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 205 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY REGION,
2024–2031 (USD MILLION) 189
TABLE 206 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 191
TABLE 207 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 192
TABLE 208 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 192
TABLE 209 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 192
TABLE 210 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 211 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 212 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 193
TABLE 213 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 194
TABLE 214 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 215 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 194
TABLE 216 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 195
TABLE 217 NORTH AMERICA: MACROECONOMIC INDICATORS 195
TABLE 218 US: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196
TABLE 219 US: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 197
TABLE 220 US: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 221 US: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 198
TABLE 222 US: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 198
TABLE 223 US: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 198
TABLE 224 US: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 199
TABLE 225 US: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 226 US: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 199
TABLE 227 US: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 200
TABLE 228 CANADA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 201
TABLE 229 CANADA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 201
TABLE 230 CANADA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 231 CANADA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 202
TABLE 232 CANADA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 203
TABLE 233 CANADA: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 203
TABLE 234 CANADA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 203
TABLE 235 CANADA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 236 CANADA: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 204
TABLE 237 CANADA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 204
TABLE 238 NORTH AMERICA: BLOOD CULTURE SETS VOLUME, 2024–2031 (MN UNITS) 205
TABLE 239 EUROPE: BLOOD CULTURE TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 206
TABLE 240 EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 207
TABLE 241 EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 207
TABLE 242 EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 243 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 208
TABLE 244 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 208
TABLE 245 EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 208
TABLE 246 EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 209
TABLE 247 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 248 EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 209
TABLE 249 EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 210
TABLE 250 EUROPE: MACROECONOMIC INDICATORS 210
TABLE 251 GERMANY: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 211
TABLE 252 GERMANY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 212
TABLE 253 GERMANY: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 212
TABLE 254 GERMANY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 212
TABLE 255 GERMANY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 213
TABLE 256 GERMANY: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 213
TABLE 257 GERMANY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 213
TABLE 258 GERMANY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 259 GERMANY: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 214
TABLE 260 GERMANY: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 214
TABLE 261 UK: BLOOD CULTURE TESTS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216
TABLE 262 UK: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 216
TABLE 263 UK: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 264 UK: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 217
TABLE 265 UK: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 217
TABLE 266 UK: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 217
TABLE 267 UK: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 218
TABLE 268 UK: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 269 UK: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 218
TABLE 270 UK: BLOOD CULTURE TESTS MARKET, BY END USER, 2024–2031 (USD MILLION) 219
TABLE 271 FRANCE: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 220
TABLE 272 FRANCE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 220
TABLE 273 FRANCE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 274 FRANCE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 221
TABLE 275 FRANCE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 221
TABLE 276 FRANCE: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 221
TABLE 277 FRANCE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 222
TABLE 278 FRANCE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 279 FRANCE: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 222
TABLE 280 FRANCE: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 223
TABLE 281 ITALY: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 224
TABLE 282 ITALY: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 224
TABLE 283 ITALY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 284 ITALY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 225
TABLE 285 ITALY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 286 ITALY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 226
TABLE 287 ITALY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 226
TABLE 288 ITALY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 289 ITALY: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 227
TABLE 290 ITALY: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 227
TABLE 291 SPAIN: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 228
TABLE 292 SPAIN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 229
TABLE 293 SPAIN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 294 SPAIN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 229
TABLE 295 SPAIN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 230
TABLE 296 SPAIN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 230
TABLE 297 SPAIN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 230
TABLE 298 SPAIN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 299 SPAIN: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 231
TABLE 300 SPAIN: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 231
TABLE 301 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 233
TABLE 302 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 303 REST OF EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 234
TABLE 304 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 305 REST OF EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 306 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 235
TABLE 307 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 235
TABLE 308 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 309 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 236
TABLE 310 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 236
TABLE 311 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 312 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 238
TABLE 313 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 314 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 239
TABLE 315 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 316 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 240
TABLE 317 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 240
TABLE 318 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 240
TABLE 319 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 320 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 241
TABLE 321 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 241
TABLE 322 ASIA PACIFIC: MACROECONOMIC INDICATORS 242
TABLE 323 CHINA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 243
TABLE 324 CHINA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 325 CHINA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 326 CHINA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 327 CHINA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 328 CHINA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 245
TABLE 329 CHINA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 245
TABLE 330 CHINA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 331 CHINA: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 246
TABLE 332 CHINA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 333 JAPAN: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 247
TABLE 334 JAPAN: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 248
TABLE 335 JAPAN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 336 JAPAN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 248
TABLE 337 JAPAN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 338 JAPAN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 249
TABLE 339 JAPAN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 249
TABLE 340 JAPAN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 341 JAPAN: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 250
TABLE 342 JAPAN: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 250
TABLE 343 INDIA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 251
TABLE 344 INDIA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 345 INDIA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 346 INDIA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 347 INDIA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 253
TABLE 348 INDIA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 253
TABLE 349 INDIA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 253
TABLE 350 INDIA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 351 INDIA: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 254
TABLE 352 INDIA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 353 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 256
TABLE 354 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR COSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 355 REST OF ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 356 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 257
TABLE 357 REST OF ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 358 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 258
TABLE 359 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 258
TABLE 360 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 361 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 259
TABLE 362 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 259
TABLE 363 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 364 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 261
TABLE 365 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 366 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 261
TABLE 367 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 368 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 369 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 262
TABLE 370 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 263
TABLE 371 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 372 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 263
TABLE 373 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 264
TABLE 374 LATIN AMERICA: MACROECONOMIC INDICATORS 264
TABLE 375 BRAZIL: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 265
TABLE 376 BRAZIL: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 377 BRAZIL: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 378 BRAZIL: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 379 BRAZIL: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 380 BRAZIL: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 267
TABLE 381 BRAZIL: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 268
TABLE 382 BRAZIL: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 383 BRAZIL: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 268
TABLE 384 BRAZIL: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 269
TABLE 385 MEXICO: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 270
TABLE 386 MEXICO: BLOOD CULTURE TESTS MARKET FOR COSUMABLES, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 387 MEXICO: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 388 MEXICO: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 389 MEXICO: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 390 MEXICO: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 271
TABLE 391 MEXICO: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 272
TABLE 392 MEXICO: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES,
BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 393 MEXICO: BLOOD CULTURE TESTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 272
TABLE 394 MEXICO: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 273
TABLE 395 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 274
TABLE 396 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 397 REST OF LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 275
TABLE 398 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 399 REST OF LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 400 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 276
TABLE 401 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276
TABLE 402 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 403 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277
TABLE 404 REST OF LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 277
TABLE 405 MIIDLE EAST & AFERICA: MACROECONOMIC INDICATORS 279
TABLE 406 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 279
TABLE 407 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR COSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 408 MIDDLE EAST & AFRICA: BLOOD CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 409 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 410 MIDDLE EAST & AFRICA: SUPPORTING LABORATORY EQUIPMENT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 411 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 281
TABLE 412 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 281
TABLE 413 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 414 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282
TABLE 415 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY END USER,
2024–2031 (USD MILLION) 282
TABLE 416 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BLOOD CULTURE TESTS MARKET, JANUARY 2023−AUGUST 2026 283
TABLE 417 BLOOD CULTURE TESTS MARKET: DEGREE OF COMPETITION 286
TABLE 418 BLOOD CULTURE TESTS MARKET: REGION FOOTPRINT 290
TABLE 419 BLOOD CULTURE TESTS MARKET: OFFERING FOOTPRINT 291
TABLE 420 BLOOD CULTURE TESTS MARKET: METHOD FOOTPRINT 291
TABLE 421 BLOOD CULTURE TESTS MARKET: TECHNOLOGY FOOTPRINT 292
TABLE 422 BLOOD CULTURE TESTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 294
TABLE 423 BLOOD CULTURE TESTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 294
TABLE 424 BLOOD CULTURE TESTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 295
TABLE 425 BLOOD CULTURE TESTS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 297
TABLE 426 BLOOD CULTURE TESTS MARKET: DEALS, JANUARY 2023–AUGUST 2026 298
TABLE 427 WATERS CORPORATION: COMPANY OVERVIEW 299
TABLE 428 WATERS CORPORATION: PRODUCTS OFFERED 300
TABLE 429 WATERS CORPORATION: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 302
TABLE 430 WATERS CORPORATION: DEALS, JANUARY 2023–JUNE 2026 302
TABLE 431 BIOMÉRIEUX: COMPANY OVERVIEW 304
TABLE 432 BIOMÉRIEUX: PRODUCTS OFFERED 305
TABLE 433 BIOMÉRIEUX: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 307
TABLE 434 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 308
TABLE 435 THERMO FISHER SCIENTIFIC, INC.: PRODUCTS OFFERED 309
TABLE 436 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2023–JUNE 2026 310
TABLE 437 DANAHER CORPORATION: COMPANY OVERVIEW 312
TABLE 438 DANAHER CORPORATION: PRODUCTS OFFERED 313
TABLE 439 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 315
TABLE 440 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 316
TABLE 441 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 317
TABLE 442 DIASORIN S.P.A.: COMPANY OVERVIEW 319
TABLE 443 DIASORIN S.P.A.: PRODUCTS OFFERED 320
TABLE 444 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 322
TABLE 445 BRUKER CORPORATION: COMPANY OVERVIEW 323
TABLE 446 BRUKER CORPORATION: PRODUCTS OFFERED 324
TABLE 447 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 325
TABLE 448 BRUKER CORPORATION: DEALS, JANUARY 2023–JUNE 2026 326
TABLE 449 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 327
TABLE 450 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 328
TABLE 451 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 329
TABLE 452 AUTOBIO DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 330
TABLE 453 AUTOBIO DIAGNOSTICS CO., LTD.: PRODUCTS OFFERED 331
TABLE 454 AUTOBIO DIAGNOSTICS CO., LTD.: DEALS, JANUARY 2023–JUNE 2026 332
TABLE 455 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 333
TABLE 456 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 334
TABLE 457 HIMEDIA LABORATORIES PVT. LTD.: COMPANY OVERVIEW 335
TABLE 458 BIOBASE GROUP: COMPANY OVERVIEW 336
TABLE 459 LABOTRONICS SCIENTIFIC: COMPANY OVERVIEW 337
TABLE 460 HARDY DIAGNOSTICS: COMPANY OVERVIEW 338
TABLE 461 BIOLOG, INC.: COMPANY OVERVIEW 339
TABLE 462 ZHUHAI DEER BIOENGINEERING CO., LTD.: COMPANY OVERVIEW 340
TABLE 463 ZHUHAI MEIHUA MEDICAL TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 341
TABLE 464 FISON INSTRUMENTS LTD.: COMPANY OVERVIEW 342
TABLE 465 BINDER GMBH: COMPANY OVERVIEW 343
TABLE 466 LABTRON EQUIPMENT LTD.: COMPANY OVERVIEW 344
TABLE 467 LABNICS LTD.: COMPANY OVERVIEW 345
TABLE 468 COPAN ITALIA S.P.A.: COMPANY OVERVIEW 346
TABLE 469 GREINER BIO-ONE INTERNATIONAL GMBH: COMPANY OVERVIEW 347
TABLE 470 LIOFILCHEM S.R.L.: COMPANY OVERVIEW 348
TABLE 471 TITAN BIOTECH LTD.: COMPANY OVERVIEW 349
TABLE 472 BLOOD CULTURE TESTS MARKET: RISK ASSESSMENT 362

LIST OF FIGURES

FIGURE 1 BLOOD CULTURE TESTS MARKET SEGMENTATION & REGIONAL SCOPE 39
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 43
FIGURE 3 GLOBAL BLOOD CULTURE TESTS MARKET, 2024–2031 44
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BLOOD CULTURE TESTS MARKET, 2023–2025 44
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BLOOD CULTURE TESTS MARKET 45
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN BLOOD CULTURE TESTS MARKET, 2026–2031 46
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47
FIGURE 8 RISING BURDEN OF BLOODSTREAM INFECTIONS AND ANTIMICROBIAL RESISTANCE TO DRIVE MARKET GROWTH 48
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49
FIGURE 10 AUTOMATED BLOOD CULTURES SEGMENT TO LEAD MARKET DURING
FORECAST PERIOD 49
FIGURE 11 CULTURE-BASED TECHNOLOGIES SEGMENT TO LEAD MARKET DURING
FORECAST PERIOD 50
FIGURE 12 BACTEREMIA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50
FIGURE 13 HOSPITAL-LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 51
FIGURE 15 BLOOD CULTURE TESTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 52
FIGURE 16 BLOOD CULTURE TESTS MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 17 BLOOD CULTURE TESTS MARKET: SUPPLY CHAIN ANALYSIS 67
FIGURE 18 BLOOD CULTURE TESTS MARKET: VALUE CHAIN ANALYSIS 68
FIGURE 19 BLOOD CULTURE TESTS MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 20 BLOOD CULTURE TESTS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 21 NUMBER OF DEALS & FUNDING ACTIVITIES IN BLOOD CULTURE TESTS MARKET 76
FIGURE 22 PATENT ANALYSIS FOR BLOOD CULTURE TESTS, JANUARY 2015–DECEMBER 2025 83
FIGURE 23 MARKET POTENTIAL OF AI IN BLOOD CULTURE TESTS MARKET 86
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 93
FIGURE 25 KEY BUYING CRITERIA, BY OFFERING 94
FIGURE 26 NORTH AMERICA: BLOOD CULTURE TESTS MARKET SNAPSHOT 191
FIGURE 27 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET SNAPSHOT 237
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN BLOOD CULTURE TESTS MARKET,
2023–2025 (USD MILLION) 285
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BLOOD CULTURE
TESTS MARKET, 2025 286
FIGURE 30 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 289
FIGURE 31 BLOOD CULTURE TESTS MARKET: COMPANY FOOTPRINT 290
FIGURE 32 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 293
FIGURE 33 EV/EBITDA OF KEY VENDORS 295
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 296
FIGURE 35 BLOOD CULTURE TESTS MARKET: BRAND/PRODUCT COMPARISON FOR AUTOMATED BLOOD CULTURE SYSTEMS 296
FIGURE 36 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 300
FIGURE 37 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 305
FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2025) 309
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 313
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 316
FIGURE 41 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 320
FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2025) 324
FIGURE 43 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY SNAPSHOT (2025) 328
FIGURE 44 AUTOBIO DIAGNOSTICS CO., LTD.: COMPANY SNAPSHOT (2025) 331
FIGURE 45 BLOOD CULTURE TESTS MARKET: RESEARCH DESIGN METHODOLOGY 350
FIGURE 46 PRIMARY SOURCES 353
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 355
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 356
FIGURE 49 GLOBAL BLOOD CULTURE TESTS MARKET: REVENUE SHARE ANALYSIS 357
FIGURE 50 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 358
FIGURE 51 TOP-DOWN APPROACH 359
FIGURE 52 DATA TRIANGULATION METHODOLOGY 360
FIGURE 53 PARAMETRIC ASSUMPTIONS 361

---

---